Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells

Blood

Volumn 102, Issue 1, 2003, Pages 237-245

  Witcher, Michael ^b   Ross, Douglas T ^b   Rousseau, Caroline ^b   Deluca, Leslie ^b   Miller Jr , Wilson H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 3; PROTEIN DIF 2; RETINOIC ACID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL LINE; TUMOR DIFFERENTIATION;

EID: 0038305473     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2725     Document Type: Article

References (74)

1. Nervi C, Ferrara FF, Fanelli M, et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARα fusion protein. Blood. 1998;92:2244-2251.
2. Nason-Burchenal K, Takle G, Pace U, et al. Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene. 1998;17:1759-1768.
3. Morosetti R, Park DJ, Chumakov AM, et al. A novel, myeloid transcription factor, C/EBP epsilon, is upregulated during granulocytic, but not monocytic, differentiation. Blood. 1997;90:2591-2600.
4. Park DJ, Chumakov AM, Vuong PT, et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyetocytic leukemia treatment. J Clin Invest. 1999;103:1399-1408.
5. Jones LC, Lin ML, Chen SS, et al. Expression of C/EBPβ from the C/ebpα gene locus is sufficient for normal hematopoiesis in vivo. Blood. 2002;99:2026-2032.
6. Casini T, Pelicci PG. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene. 1999;18:3235-3243.
7. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor: correlation with retinoid induction of U937 cell differentiation. J Biol Chem. 1996;271:31723-31728.
8. Chelbi-Alix MK, Pelicano L. Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Leukemia. 1999;13:1167-1174.
9. Shimizu T, Takeda K. Induction of retinoic acid receptor-α by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines. Cancer Res. 2000;60:4544-4549.
10. Kolla V, Weihua X, Kalvakolanu DV. Modulation of interferon action by retinoids: induction of murine STAT1 gene expression by retinoic acid. J Biol Chem. 1997;272:9742-9748.
11. Yang JB, Duan ZJ, Yao W, et al. Synergistic transcriptional activation of human Acyl-coenzyme A: cholesterol acyltransferase-1 gene by interferon-gamma and all-trans-retinoic acid THP-1 cells. J Biol Chem. 2001;276:20989-20998.
12. Gianni M, Terao M, Zanotta S, Barbui T, Rambaldi A, Garattini E. Retinoic acid and granulocyte colony-stimulating factor synergistically induce leukocyte alkaline phosphatase in acute promyelocytic leukemia cells. Blood. 1994;83:1909-1921.
13. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999;93:2478-2484.
14. Usuki K, Nishizawa Y, Endo M, et al. Administration of granulocyte colony-stimulating factor during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Int J Hematol. 1996;64:213-219.
15. Hofmann WK, Ganser A, Seipelt G, et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematology. 1999;78:125-130.
16. Berg WJ, Nanus DM, Leung A, et al. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-α-2a. Clin Cancer Res. 1999;5:1671-1675.
17. Barnea E, Bergman Y. Synergy of SF1 and RAR in activation of Oct-3/4 promoter. J Biol Chem. 2000;275:6608-6619.
18. Mudipalli A, Li Z, Hromchak R, Bloch A. NF-κB (p65/RelA) as a regulator of TNFα-mediated ML-1 cell differentiation. Leukemia. 2001;15:808-813.
19. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G. Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells. J Biol Chem. 2000;275:3081-3087.
20. Kuwano K, Hara N. Signal transduction pathways of apoptosis and inflammation induced by the tumor necrosis factor receptor family. Am J Respir Cell Mol Biol. 2000;22:147-149.
21. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000;191:275-286.
22. Schnurr M, Then F, Galambos P, et al. Extracellular ATP and TNF-α synergize in the activation and maturation of human dendritic cells. J Immunol. 2000;165:4704-4749.
23. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene. 1999;18:6910-6924.
24. Schmitz ML, Baeuerle PA. The p65 subunit is responsible for the strong transcription activating potential of NF-κB. EMBO J. 1990;10:3805-3817.
25. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 1999;18:6853-6866.
26. Manna SK, Aggarwal BB. All-trans-retinoic acid up-regulates TNF receptors and potentiates TNF-induced activation of nuclear factors-κB, activated protein-1 and apoptosis in human lung cancer cells. Oncogene. 1999;19:2110-2119.
27. Harant H, de Martin R, Andrew PJ, Foglar E, Dittrich C, Lindrey IJ. Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-α involves the transcription factor NF-κB [abstract]. J Biol Chem. 1996;271:26954.
28. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 2001;7:680-686.
29. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000;24:227-235.
30. Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol. 2001;166:7128-7135.
31. Richard M, Louahed J, Demoulin JB, Renauld JC. Interleukin-9 regulates NF-κB activity through BCL3 gene induction. Blood. 1999;93:4318-4327.
32. Jang MK GY, Sohn YC, Kim YS, et al. Ca2+/calmodulin-dependent protein kinase IV stimulates nuclear factor-κB transactivation via phosphorylation of the p65 subunit. J Biol Chem. 2001;276:20005-20010.
33. Momparler RL, Dore BT, Momparler LF. Effect of 5-aza-2′-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells. Cancer Lett. 1990;54:21-28.
34. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
35. Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller WH Jr. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood. 1996;88:2671-2682.
36. Murate T, Suzuki M, Hattori M, et al. Up-regulation of acid sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J Biol Chem. 2002;277:9936-9943.
37. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993;74:423-431.
38. Khanna-Gupta A, Kolibaba K, Zibello TA, Berliner N. NB4 cells show bilineage potential and an aberrant pattern of neutrophil secondary granule protein gene expression. Blood. 1994;84:294-301.
39. Dimberg A, Nilsson K, Öberg F. Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood. 2000;96:2870-2878.
40. D'Addario M, Wainberg MA, Hiscott J. Activation of cytokine genes in HIV-1-infected myelomonoblastic cells by phorbol ester and tumor necrosis factor. J Immunol. 1992;148:1222-1229.
41. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-κB in the resolution of inflammation. Nat Med. 2001;7:1291-1297.
42. Saccani S, Pantano S, Natoli G. Two waves of nuclear factor κB recruitment to target promoters. J Exp Med. 2001;193:1351-1359.
43. Chen LF, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science. 2001;293:1653-1657.
44. Zhong H, Voll RE, Ghosh S. Phosphorylatlon of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell. 1998;1:661-671.
45. Cheshire JL, Baldwin AS Jr. Synergistic activation of NF-κB by tumor necrosis factor alpha and gamma interferon via enhanced IκB alpha degradation and de novo IκBβ degradation. Mol Cell Biol. 1997;17:6746-6754.
46. Sareneva T, Julkunen I, Matikainen S. IFN-α and IL-12 induce IL-18 receptor gene expression in human NK and T cells [abstract]. J Immunol. 2000;165:1933.
47. Karin M. How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene. 1999;18:6867-6874.
48. Bours V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 1993;72:729-739.
49. Bundy DL, McKeithan TW. Diverse effects of BCL3 phosphorylation on its modulation of NF-κB p52 homodimer binding to DNA. J Biol Chem. 1997;272:33132-33139.
50. Caamano JH, Perez P, Lira SA, Bravo R. Constitutive expression of Bcl-3 in thymocytes increases the DNA binding of NF-κB1 (p50) homodimers in vivo. Mol Cell Biol. 1996;16:1342-1348.
51. Pietzsch A, Buchler C, Aslanidis C, Schmitz G. Identification and characterization of a novel monocyte/macrophage differentiation-dependent gene that is responsive to lipopolysaccharide, ceramide, and lysophosphatidylcholine. Biochem Biophys Res Commun. 1997;235:4-9.
52. Yamamoto H, Kishimoto T, Minamoto S. NF-κB activation in CD27 signaling: involvement of TNF receptor-associated factors in its signaling and identification of functional region of CD27. J Immunol. 1998;161:4753-4759.
53. Song HY, Rothe M, Goeddel DV. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc Natl Acad Sci U S A. 1996;93:6721-6725.
54. Tobler A, Munker R, Heitjan D, Koeffler HP. In vitro interaction of recombinant tumor necrosis factor alpha and all-trans-retinoic acid with normal and leukemic hematopoietic cells [abstract]. Blood. 1987;70:1940.
55. Quenech Du N, Ruchaud S, Khelef N, Guiso N, Lanotte M. A sustained increase in the endogenous level of cAMP reduces the retinoid concentration required for APL cell maturation to near physiological levels. Leukemia. 1998;12:1829-1833.
56. Benoit G, Roussel M, Pendino F, Segal-Bendirdjian E, Lanotte M. Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation. Oncogene. 2001;20:7161-7177.
57. Kastner P, Chan S. Function of RARα during the maturation of neutrophils. Oncogene. 2001;20:7178-7185.
58. Ruchaud S, Duprez E, Gendron MC, et al. Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc Natl Acad Sci U S A. 1994;91:8428-8432.
59. Chen A, Licht JD, Wu Y, Hellinger N, Scher W, Waxman S. Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood. 1994;84:2122-2129.
60. Pietzsch A, Buchler C, Schmitz G. Genomic organization, promoter cloning, and chromosomal localization of the Dif-2 gene. Biochem Biophys Res Commun. 1998;245:651-657.
61. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science. 1998;281:998-1001.
62. Benoit GR, Flexor M, Besancon F, et al. Autonomous retinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. Mol Endocrinol. 2001;15:1154-1169.
63. Craig R. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia. 2002;16:444-454.
64. Kieslinger M, Woldman I, Moriggl R, et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 2000;14:232-244.
65. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372-377.
66. Kuwano K, Hara N. Signal transduction pathways of apoptosis and inflammation induced by the tumor necrosis factor receptor family. Am J Respir Cell Mol Biol. 2000;22:147-149.
67. Moreb JS, Schweder M. Human A1, a Bcl-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors. Leukemia. 1997;11:998-1004.
68. Moulding DA, Quayle JA, Hart CA, Edwards SW. Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival. Blood. 1998;92:2495-2502.
69. Kianmanesh A, Hackett NR, Lee JM, Kikuchi T, Korst RJ, Crystal RG. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity. Hum Gene Ther. 2001;12:2035-2049.
70. Kramer G, Steiner GE, Sokol P, et al. Local intratumoral tumor necrosis factor-α and systemic IFN-α2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res. 2001;21:475-484.
71. Alexander HR, Libutti SK, Bartlett DL, Puhimann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062-3070.
72. Janik JE, Miller LL, Kopp WC, et al. Treatment with tumor necrosis factor-α and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients. Clin Immunol. 1999;93:209-221.
73. Van Molle W, Wielockx B, Mahieu T, et al. HSP70 protects against TNF-induced lethal inflammatory shock. Immunity. 2002;16:685-695.
74. Chen Z, Huang H, Chang T, et al. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Ther. 2002;9:778-786.